The Drug Development Program at Princess Margaret Hospital is an exciting initiative, focusing on phase I and II oncology clinical trials. In addition to implementing high quality studies with novel anti-cancer agents, we will continue to provide optimal patient care.
A major component of the Drug Development Program is the PMH Phase II Consortium, which was selected as the first Canadian centre to carry out National Cancer Institiute (NCI)-sponsored phase II clinical trials of new anti-cancer drugs in 2001. Since its inception, the Consortium has seen more than 1200 patients enrolled in over sixty trials.
News and events details current issues and events.